Nykode Therapeutics ASA announced a collaboration with the GOG Foundation Inc. to conduct a clinical trial of VB10.16 in combination with an immune checkpoint inhibitor for the treatment of advanced cervical cancer in the U.S. The VB-C-04 trial will evaluate the combination therapies in patients with cervical cancer that have progressed following first line treatment. Nykode has previously reported positive interim data from the Phase 2 VB-C-02 trial in Europe in patients with heavily pre-treated advanced cervical cancer. VB10.16, wholly owned by Nykode, is a potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate in development for the treatment of HPV16-positive cancers.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.01 NOK | +1.90% | +1.28% | -29.86% |
05-14 | Transcript : Nykode Therapeutics AS, Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.86% | 458M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- VACC Stock
- News Nykode Therapeutics
- Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer